$RLYB

Rallybio Corp

Rallybio is a clinical-stage biotechnology company developing therapies for patients with severe and rare diseases. Its main programs include RLYB116, a C5 inhibitor in clinical development for disorders involving complement dysregulation, and RLYB332, a preclinical antibody program for diseases involving iron overload. Rallybio has completed two Phase 1 trials of RLYB116 in healthy participants and conducts limited research and development operations. Rallybio is party to a proposed merger with Candid, a clinical-stage biotechnology company developing T-cell engager therapeutics for autoimmune diseases. Its business also includes collaborations to discover and develop rare disease therapies, and it may receive milestone payments and royalties from the sale of its preclinical REV102 program. Rallybio is headquartered in New Haven, Connecticut.

0
3
1
—
$10K
Lieber Jonathan I
0%
See all $RLYB insider activity →
High

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

RLYB sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 4 news stories mentioning RLYB (Rallybio Corp). Coverage has skewed bearish: 0 bullish, 3 neutral, and 1 bearish.

Recent RLYB coverage spans mergers & acquisitions, corporate actions and earnings.

In the last 30 days, RLYB insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($10K). The most active reporter was Lieber Jonathan I, Chief Financial Officer, with 1 filing.

What's driving RLYB

  • The cash distribution creates buying pressure as investors seek to hold shares through the due‑bill period, while the merger may add uncertainty.

    SEC EDGAR 8-K · Nov 12, 2026

  • The split reduces share count and may improve price perception, while the merger adds upside potential.

    tradingview.com · Nov 10, 2026

  • The reverse split may cause short‑term price volatility and pressure as the share count halves and merger uncertainty remains.

    SEC EDGAR 8-K · Nov 10, 2026

  • Delay in merger closing and potential delay to cash distribution/ex-dividend timing likely increases deal uncertainty and near-term volatility.

    tradingview.com · Nov 6, 2026

  • The postponement introduces uncertainty and likely pressures the stock lower.

    SEC EDGAR 8-K · Nov 6, 2026

AlphAI scores every news story that mentions RLYB with an AI model for sentiment and relevance, and aggregates insider trades from Rallybio Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $RLYB

Score
$RLYBHighM&A· target · definitive

Rallybio Corporation announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) announced today that, subject to the satisfaction or waiver of any outstanding closing conditions, it anticipates the transactions contemplated by the Agreement and Plan of Merger and Reorganization (the “Merger Agreeme

$RLYBMedStock split· reverse

Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Rallybio Announces Reverse Stock Split of Common Stock in Connection with the Proposed Merger with Avenzo EAST BERLIN, Conn., November 10, 2026 – Rallybio Corporation (Nasdaq: RLYB) today announced that it will effect a one-for-two reverse stock split of its issued a

Rallybio Corporation previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. Rallybio Corporation (the “Company”) previously disclosed that, subject to the satisfaction or waiver of any outstanding closing conditions, the Company anticipated the transactions contemplated by the Agreement and Plan of Merger and Reorganization, dated

$RLYBLowM&A· acquirer · definitive

Rallybio Corp (RLYB): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Rallybio Corp (RLYB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. 2026 Equity Incentive Plan At the annual meeting of the stockholders of Rallybio Corporation (“Rallybio” or the “Company”)

$RLYBHighAI 8/10Dividend· special · $13.56

The Rallybio Corporation, a Delaware corporation, entered into an Agreement and Plan of Merger and Reorganization with Avenzo Therapeutics, Inc., a Delaware…

Rallybio Corp (RLYB) filed an SEC Form 8-K — Other Events. Item 8.01 Other Events. As previously disclosed, on May 31, 2026, the Rallybio Corporation, a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Avenzo Therapeutics, Inc., a Delaware corporation (“Av

Related tickers